Evidence map›Paper›PMID 36600203›Full record

ArticleBMC cancer2023

Inference of core needle biopsy whole slide images requiring definitive therapy for prostate cancer.

Masayuki Tsuneki, Makoto Abe, Shin Ichihara, Fahdi Kanavati

Abstract read
PubMed Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Masayuki TsunekiMedmain Research, Medmain Inc., 2-4-5-104, Akasaka, Chuo-ku, Fukuoka, 810-0042, Japan. tsuneki@medmain.com.
Makoto AbeDepartment of Pathology, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, 320-0834, Japan.
Shin IchiharaDepartment of Surgical Pathology, Sapporo Kosei General Hospital, 8-5 Kita-3-jo Higashi, Chuo-ku, Sapporo, 060-0033, Japan.
Fahdi KanavatiMedmain Research, Medmain Inc., 2-4-5-104, Akasaka, Chuo-ku, Fukuoka, 810-0042, Japan.

Funding

New Energy and Industrial Technology Development Organization,Japan JPNP14012
6 · The paper itself

Abstract

backgroundProstate cancer is often a slowly progressive indolent disease. Unnecessary treatments from overdiagnosis are a significant concern, particularly low-grade disease. Active surveillance has being considered as a risk management strategy to avoid potential side effects by unnecessary radical treatment. In 2016, American Society of Clinical Oncology (ASCO) endorsed the Cancer Care Ontario (CCO) Clinical Practice Guideline on active surveillance for the management of localized prostate cancer.

methodsBased on this guideline, we developed a deep learning model to classify prostate adenocarcinoma into indolent (applicable for active surveillance) and aggressive (necessary for definitive therapy) on core needle biopsy whole slide images (WSIs). In this study, we trained deep learning models using a combination of transfer, weakly supervised, and fully supervised learning approaches using a dataset of core needle biopsy WSIs (n=1300). In addition, we performed an inter-rater reliability evaluation on the WSI classification.

resultsWe evaluated the models on a test set (n=645), achieving ROC-AUCs of 0.846 for indolent and 0.980 for aggressive. The inter-rater reliability evaluation showed s-scores in the range of 0.10 to 0.95, with the lowest being on the WSIs with both indolent and aggressive classification by the model, and the highest on benign WSIs.

conclusionThe results demonstrate the promising potential of deployment in a practical prostate adenocarcinoma histopathological diagnostic workflow system.

Indexed as

AdenocarcinomaProstatic NeoplasmsBiopsy, Large-Core NeedleHumansMaleOntarioReproducibility of ResultsActive surveillanceDeep learningFully supervised learningProstate cancerTransfer learningWeakly supervised learning

Identifiers

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.